DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and international markets, beating consensus expectations and pairing this with guidance ...
If you are wondering whether DexCom's current share price really reflects what you are getting for your money, you are not alone. The stock last closed at US$73.67, with returns of 4.2% over 7 days, 9 ...
Pre-earnings options volume in DexCom (DXCM) is 2.4x normal with puts leading calls 7:5. Implied volatility suggests the market is anticipating a move near 6.7%, or $5.59, after results are released.
DexCom Inc (NASDAQ:DXCM) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. As of the January 28 closing, DexCom Inc. (NASDAQ:DXCM) had highly bullish sentiment ...
Wondering whether DexCom's current share price lines up with its underlying worth, or if the market is missing something ...
DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A robust first-quarter 2024 performance, along with a series of favorable coverage decisions ...
DexCom stock snapshot and recent performance DexCom (DXCM) has been drawing attention after recent price moves, with the shares last closing at $69.54. For context, the stock shows a 0.4% gain over ...
For folks managing their diabetes with Dexcom, Siri can now answer one more question: What is my glucose level? This morning Dexcom announced a slew of new companion app features for the Dexcom G6 ...
DexCom (NASDAQ:DXCM) stock saw a notable increase of 16% on Friday following the announcement of its Q1 earnings and a share buyback program. The company’s first-quarter sales hit $1.04 billion, ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...